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In drug discovery, the occurrence of false positives is a major hurdle in the search for lead compounds 
that can be developed into drugs. A small-molecular-weight compound that inhibits dengue virus protease 
at low micromolar levels was identified in a screening campaign. Binding to the enzyme was confirmed by 
isothermal titration calorimetry (ITC) and nuclear magnetic resonance (NMR). However, a structure-
activity relationship study that ensued did not yield more potent leads. To further characterize the 
parental compound and its analogues, we developed a high-speed, low-cost, quantitative fluorescence 
quenching assay. We observed that specific analogues quenched dengue protease fluorescence and 
showed variation in IC(50) values. In contrast, nonspecifically binding compounds did not quench its 
fluorescence and showed similar IC(50) values with steep dose-response curves. We validated the assay 
using single Trp-to-Ala protease mutants and the competitive protease inhibitor aprotinin. Specific 
compounds detected in the binding assay were further analyzed by competitive ITC, NMR, and surface 
plasmon resonance, and the assay's utility in comparison with these biophysical methods is discussed. 
The sensitivity of this assay makes it highly useful for hit finding and validation in drug discovery. 
Furthermore, the technique can be readily adapted for studying other protein-ligand interactions. 
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a b s t r a c t
In drug discovery, the occurrence of false positives is a major hurdle in the search for lead compounds
that can be developed into drugs. A small-molecular-weight compound that inhibits dengue virus pro-
tease at low micromolar levels was identified in a screening campaign. Binding to the enzyme was
confirmed by isothermal titration calorimetry (ITC) and nuclear magnetic resonance (NMR). However,
a structure–activity relationship study that ensued did not yield more potent leads. To further char-
acterize the parental compound and its analogues, we developed a high-speed, low-cost, quantitative
fluorescence quenching assay. We observed that specific analogues quenched dengue protease fluores-
cence and showed variation in IC50 values. In contrast, nonspecifically binding compounds did not
quench its fluorescence and showed similar IC50 values with steep dose–response curves. We vali-
dated the assay using single Trp-to-Ala protease mutants and the competitive protease inhibitor apro-
tinin. Specific compounds detected in the binding assay were further analyzed by competitive ITC,
NMR, and surface plasmon resonance, and the assay’s utility in comparison with these biophysical
methods is discussed. The sensitivity of this assay makes it highly useful for hit finding and validation
in drug discovery. Furthermore, the technique can be readily adapted for studying other protein–
ligand interactions.
 2009 Elsevier Inc. All rights reserved.
High-throughput screening (HTS)2 is a major method in drug
discovery for new small lead molecules. In high-throughput enzyme
inhibition assays, more than a million compounds are usually tested
for their ability to inactivate the target enzyme. Often the process in-
volves two consecutive screens [1,2]. The first screen identifies com-
pounds that inhibit the enzymatic activity and is usually performed
at a single compound concentration. The second screen confirms the
positive hits from the former one by measuring IC50 values (i.e., the
concentration of compound needed to obtain 50% inhibition of the
enzyme in the in vitro assay). After the second round of screening,
one may still be left with hundreds of lead candidates, many of
which could be false positives [3].
Often one or more candidate lead compound classes are chosen
as starting points for structure–activity relationship (SAR) studies.
Compounds are chemically derivatized so as to improve their
inhibitory capacity or IC50. IC50 measurements alone, however,
contain no information on the inhibitory mechanism. It has been
widely documented that an IC50 value can arise from many mech-
anisms besides specific inhibition such as target sequestration,
compound aggregation, and interference with the enzymatic assay
[4–6]. Thus, IC50 values may serve as a disqualifying parameter (if
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the compound is only weakly active) but cannot constitute the
only qualifying parameter for identification of a lead compound gi-
ven the occurrence of the false positives mentioned above.
It is crucial, therefore, to have additional screening methods in
drug discovery to determine the specificity of a compound for the
target so as to deliver high-quality candidate compounds for lead
generation. Because dozens of compounds are usually evaluated
during hit confirmation and hit-to-lead chemistry, additional
screening methods must satisfy three requirements: (i) low cost
(in terms of amounts of compound and protein needed), (ii) high
throughput, and (iii) the ability to identify specific binding.
This article reports the development of a selective high-
throughput binding assay in the context of anti-dengue drug dis-
covery. Dengue virus (DENV) protease is an obvious target for
anti-dengue drug development [7,8] because it plays a key role
in the replication of the virus by cleaving the viral polyprotein pre-
cursor after translation. The protease domain is contained in non-
structural protein 3 (NS3) [9], and its activity is greatly enhanced
by interactions with the NS2B protein, which acts as its cofactor
[10,11]. Several efforts to find inhibitors for different flavivirus pro-
teases (West Nile virus [WNV], dengue, and yellow fever virus
[YFV]) have been reported, with several studies focusing on pep-
tidic substrate-based inhibitors [12–17]. Nonpeptidic inhibitors
have been identified by in vitro screening [18–20] or in silico
throughput docking [21]. Most of these compounds do not possess
the appropriate properties for drug development, either because
the scaffold is too labile [15–17,19] or because the inhibitors bind
too weakly [18,20].
Our attempts to identify a nonpeptidic inhibitor of dengue pro-
tease led to establishment of a simple and efficient binding assay
based on tryptophan fluorescence as described in this article. Com-
pound binding in the protease catalytic pocket was detected by
F}orster resonance energy transfer (FRET) between the ligands
and nearby Trp residues and was validated using single Trp-to-
Ala protease mutants and the competitive inhibitor aprotinin.
The assay provides quantitative compound binding affinities and
identifies promiscuous inhibitors in an inexpensive way that is
compatible with a high-throughput setup.
Materials and methods
Materials
All compounds (1–9, Bz-nKRR-H) were chemically synthesized
in-house. Fluorogenic peptide substrate Bz-Nle-Lys-Arg-Arg-AMC
was purchased from LSU Health Sciences Center (New Orleans,
LA, USA), and bovine pancreatic trypsin inhibitor was purchased
from Sigma–Aldrich (St. Louis, MO, USA). Polymerase chain reac-
tion (PCR) was carried out using Turbo Pfu polymerase from Strat-
agene (La Jolla, CA, USA). Restriction enzymes and modifying
enzymes were purchased from New England Biolabs (Beverly,
MA, USA). Oligonucleotides were synthesized by Research Biolabs
(Singapore).
Chemistry
All compounds generated in Fig. 1 were determined to have
more than 95% purity by high-performance liquid chromatography
(HPLC) (see Supplementary material).
Cloning of DENV2 CF40-gly-NS3pro185 W mutant constructs
All Trp mutants were generated with overlapping PCR using the
plasmid DENV2 TSV01 pET15b-CF40-gly-NS3pro185 as a template
[22]. To obtain cNS2B with Trp mutations, PCR was carried out
using the forward primer NS2BcfXhoI-F [22] and reverse primers
W5A-REV, W50A-REV, W69A-REV, W83A-REV, and W89A-REV,
respectively (see Table S1 in Supplementary material). To obtain
NS3pro185 with W mutations, PCR was carried out using the for-
ward primers W5A-FOR, W50A-FOR, W69A-FOR, W83A-FOR, and
W89A-FOR, respectively (see Table S1) and reverse primer
NS3pro185BamHI-R [22]. The two products were joined in the sec-
ond round of PCR using the primer pair NS2BcfXhoI-F and
NS3pro185BamHI-R to generate the individual CF40-gly-
NS3pro185 W mutants. The overlapped PCR products were di-
gested with XhoI and BamHI and were ligated into the same sites
in pET15b.
Protein expression and purification
Expression and purification of DENV2 CF40-gly-NS3pro185 has
been described previously [22]. Briefly, Escherichia coli BL21-
CodonPlus(DE3)-RIL (Stratagene) transformed with these plasmids
were grown in Luria–Bertani (LB) broth supplemented with ampi-
cillin (100 mg/ml) and chloramphenicol (50 mg/ml) at 37 C until
OD600 reached approximately 0.5. Protein expression was induced
with 0.4 mM isopropyl b-D-thiogalactoside (IPTG) at 16 C for 20 h.
Cells were harvested by centrifugation and resuspended in 4 ml of
phosphate-buffered saline containing 1% Triton X-100 (PBT). Cells
were lysed by sonication and debris was removed by centrifuga-
tion at 35,000 rpm for 30 min. The resulting protein solution was
filtered through a 0.22-lm filter and loaded onto a 5-ml HiTrap
chelating HP column (Amersham Biosciences, Piscataway, NJ,
USA) equilibrated with lysis buffer. The resin was washed with
10 column volumes of lysis buffer before bound proteins were
eluted from the column with lysis buffer and a linear gradient of
imidazole from 20 to 300 mM in the same buffer. Peak fractions
were analyzed by 10% sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS–PAGE). Positive fractions were pooled, de-
salted, and concentrated with spin concentrators (Amicon Ultra-
15, molecular weight cutoff 10,000 Da, Millipore, Billerica, MA,
USA).
Enzymatic assay
The assay has been described previously [14]. Briefly, activities
of cNS2B/NS3pro complexes were measured in a Safire2 plate read-
er (Tecan) (kex = 385 nM, kem = 465 nM) and performed in a final
volume of 50 ll containing 50 mM Tris–HCl (pH 7.5), 1 mM Chaps,
20% glycerol, and 50 lM Bz-Nle-Lys-Arg-Arg-AMC at 37 C. Control
reactions contained 50 nM CF40-gly-NS3pro185. The proteolytic
reaction was monitored by an increase in fluorescence (relative
fluorescence units [RFU]/min) that was subsequently converted
to Ms–1 from a standard 7-amino-4-methyl coumarin (AMC) cali-
bration curve. Progression curves were fitted to Michaelis–Menten
kinetics by nonlinear regression using GraphPad Prism (GraphPad
Software, San Diego, CA, USA). Steady-state kinetic constants of
each substrate were determined from triplicate measurements
and are reported as means ± standard errors (SE).
Inhibitors were assayed in a 96-well plate format using 50 mM
Tris–HCl (pH 7.5) and 1 mM Chaps in a final volume of 50 ll. Typ-
ically, protease (40 nM) was preincubated with concentrations (0–
100 lM) of test compounds at 37 C for 30 min. The reaction was
initiated by the addition of 20 lM substrate Bz-nKRR-AMC. Reac-
tion progress was monitored continuously by following the in-
crease in fluorescence on a Tecan Safire2 plate reader. IC50 values
of inhibitors were derived by fitting the calculated initial velocities
to a nonlinear regression curve using GraphPad Prism software.
Each point of the IC50 curve was measured in duplicate during a
single experiment.
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Buffer
The buffer used for absorbance spectra, titration, and isothermal
titration calorimetry (ITC) was 50 mM Tris–HCl (pH 7.5) and
50 mM NaCl.
Absorbance spectra
Absorbance spectra of compounds were measured on a Tecan
Safire2. All compounds were diluted in 90 ll of buffer to a final con-
centration of 100 lM on a UV-Star 96-well microplate (Greiner
Bio-One).
Fluorescence-monitored titrations
Two protein solutions were prepared (2–5 lM protein with and
without 40 lM compound) and were mixed in a microplate to ob-
tain 12 different compound concentrations ranging from 0 to
40 lM in approximately 3.5-lM steps. Then each dilution compris-
ing 90 ll was transferred to a UV-Star 96-well microplate. After 1 h
incubation at room temperature, fluorescence was measured at
25 C on a Tecan Safire2 with kex = 280 nm and kem = 340 nm. The
setting for slit widths depended on the protein concentration used.
For 3 lM protein, the slits were 10 and 20 mm for excitation and
emission, respectively. At the end of the measurements, 11 lM bo-
vine pancreatic trypsin inhibitor (BPTI) was added to the wells con-
taining 40 lM compound and the fluorescence was remeasured.
Binding curves were analyzed according the following two-state
model describing the formation of a 1:1 complex:
P þ L$KD PL
where P is the protein concentration, L is the ligand concentration,
and KD is the equilibrium dissociation constant.
The corresponding binding equation is
IF ¼ IF0 þ DIF
ðKD þ Pt þ LtÞ 
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ðKD þ Pt þ LtÞ2  4Lt:Pt
q
2:Pt
ð1Þ
where IF is the fluorescence intensity, IF0 is the fluorescence inten-
sity in the absence of ligand, DIF is the change in fluorescence inten-
sity on ligand binding, KD is the equilibrium dissociation constant,
and Pt and Lt are the total protein and ligand concentrations,
respectively. This equation was used to analyze the binding iso-
therms. The data were fitted using the nonlinear least squares op-
tion of GraphPad Prism software.
Fig. 1. Structures of phthalazine-based compounds. The central phthalazine ring is shown on the left. Compounds are numbered from 1 to 9, where 1 represents the parental
compound and 2 to 9 are representative modified derivatives described in the article.
Assay for inhibitors of dengue virus protease / C. Bodenreider et al. / Anal. Biochem. 395 (2009) 195–204 197
Isothermal titration calorimetry
Calorimetry experiments were performed with an Auto-ITC
microcalorimeter (Microcal). All titrations were done at 25 C. For
standard experiments, 6 lM NS2B/NS3 protease was titrated with
10-ll injections of 80 lM BPTI. Each titration included an initial 1-
ll injection. The stirring speed used was 300 rpm, and the refer-
ence power was 10 lcal/s. The heat of the last injection of each
titration series was subtracted from the titration data to account
for the heat of dilution. For competition experiments, compounds
were added to the protein in the cell. Dimethyl sulfoxide (DMSO)
was added to the BPTI solutions in the syringe to obtain equal
DMSO concentrations in the cell and in the syringe. KD values of
the compounds from competition experiments with BPTI were
estimated using the relationship [23]
KD-apparent ¼
KD-BPTI
KD-C
½C þ KD-BPTI ð2Þ
where C is compound, KD–C is the true KD value for the protease–
compound association, KD–BPTI is the KD for the protease–BPTI asso-
ciation in the absence of compound, and KD–apparent is the apparent
KD for the protease–BPTI association in the presence of compound.
Surface plasmon resonance biosensor measurements
Measurements were done on a Biacore 3000 instrument
(Biacore, Uppsala, Sweden). DEN2 CF40-gly-NS3pro186 with a C-
terminal Cys residue was immobilized via the engineered cysteine
to a level of 7000 resonance units (RU) on a carboxymethyl-dex-
tran sensor surface (CM5) using ligand–thiol coupling chemistry.
For the following procedure, each step was performed sequentially
at a flow rate of 10 ll/min: (i) 7-min injection of a mixture of 0.1 M
N-hydroxysuccinimide (NHS) and 0.4 M 1-ethyl-3-diaminopropyl-
carbodiimide (EDC), (ii) 3-min injection of 80 mM 2-(2-pyridyldi-
thio)ethaneamine (PDEA), (iii) 3.5-min injection of 1.0 M ethanol-
amine–HCl, (iv) 5-min injection of CF40-gly-NS3pro186 in
sodium acetate (pH 4.0), and (v) 7-min injection of 50 mM cysteine
in 1 M NaCl. The control surface was treated in an identical way,
omitting the injection of the protein. The inhibitors were diluted
with 50 mM phosphate buffer (pH 7.4) and 5% DMSO (final concen-
tration). The same buffer was used as running buffer throughout
the experiment. Inhibitor concentrations ranging from 0.078 to
12.5 lM were injected for 1 min sequentially over the reference
and test flow cells at a flow rate of 30 ll/min. Raw sensorgrams
were reduced and solvent-corrected with a DMSO calibration curve
[24,25] using the Scubber software package (BioLogic Software,
Campbell, Australia). Binding affinities were evaluated by fitting
the data to the 1:1 Langmuir and steady-state models using BIA-
evaluation 4.1 (Biacore).
Results
HTS/choice of lead compound/structure of inhibitor
We previously reported the development of a highly sensitive
and robust in vitro assay using the substrate Bz-nKRR-AMC for
monitoring dengue single-chain NS2B/NS3 protease activity [22].
The assay was used to test peptidic inhibitors against DENV and
WNV proteases [13,15,16]. We adapted it to a 1536-well format
and used it to screen our in-house library comprising approxi-
mately 106 compounds. One class of compound was observed to
inhibit DENV2 and WNV proteases with IC50 values of 2 and
3 lM, respectively. However, this compound class and its synthetic
intermediates were highly insoluble, and the synthesis and testing
of analogues proved to be challenging (data not shown).
A preliminary search for structurally related compounds yielded
a second compound, 1, with a more readily amenable scaffold (IC50
for DENV and WNV = 6 and 24.5 lM, respectively) (Fig. 1). Binding
of 1 to the catalytic pocket was verified by nuclear magnetic reso-
nance (NMR) spectroscopy, where the presence of 1 led to a dra-
matically improved 15N-HSQC (heteronuclear single quantum
correlation) spectrum of DENV2 protease (see Fig. S1 in Supplemen-
tary material). In the absence of resonance assignments of the pro-
tease, this provides indirect evidence for binding of 1 to its catalytic
pocket, and the same observation was made in 15N-HSQC spectra of
WNV protease. For WNV protease, NMR resonance assignments are
available and intermolecular nuclear Overhauser effects (NOEs)
indicate that 1 binds to its catalytic pocket [26].
We subsequently initiated chemistry efforts using compound 1
as the lead compound with the goal to generate a more potent
DENV protease inhibitor. In addition, in the absence of a crystal
structure of the DENV protease–inhibitor complex, the binding
mode of compound 1 was obtained by automatic docking with a
suite of programs SEED/FFLD and CHARMM minimization
[27–30] using the structure of WNV protease bound with a tetra-
peptide aldehyde inhibitor Bz-nKRR-H [31]. In this model, the cen-
tral phthalazine ring is located in a cavity of the S1 pocket and
forms a p–p interaction with the phenyl group of Tyr161. Both
charged imidazoline groups are involved in the formation of a salt
bridge or hydrogen bonds with several residues (Asp129, Gly159,
and Asn84). Furthermore, one of the NH groups linking the phenyl
and phthalazine moieties forms a hydrogen bond with Pro131
backbone carbonyl oxygen. These results are in agreement with
intermolecular NOEs reported for the homologous compound 5
[26].
The predicted binding mode of compound 1 in the protease cat-
alytic site (Fig. 2A), as well as quantum mechanical calculations to
determine the lowest energy state of compound 1 and derivatives
thereof, was used to design more analogues.
Based on these data, approximately 130 compounds were sub-
sequently synthesized. Several analogues inhibited DENV and
WNV proteases at IC50 values in the low micromolar range (repre-
sentative compounds are shown in Tables 1 and 2). Yet despite
extensive efforts, none of the analogues synthesized possessed
submicromolar inhibitory activities and no clear SAR emerged
from these studies. It is not unusual for micromolar leads with
unfavorable physical properties (e.g., solubility) to show flat SAR
and turn out to be unsuitable for lead optimization. In this case,
however, we had clear evidence that the lead compound was bind-
ing to the target protein; therefore, the absence of SAR was
puzzling.
IC50 values for different DENV serotypes
To expand our understanding of the inhibitory properties of this
class of compounds, we tested a subset on proteases from the four
different dengue serotypes (DENV1, -2, -3, and -4). NS2B/NS3 pro-
teases from DENV1–4 share between 50% and 70% sequence iden-
tity [32], and NS3 amino acid residues forming the substrate
binding pockets S1, S2, and S3 are mostly conserved [31]. Differ-
ences between the catalytic pockets of DENV1–4 arise from non-
conserved NS2B amino acid residues that participate in the
formation of S2 and S3 pockets [31]. These variations could con-
ceivably alter the binding affinities of inhibitors by changing the
NS2B structure or its ability to reorganize on ligand binding [31].
Indeed, IC50 values obtained with the peptidic inhibitor Bz-nKRR-
H varied from 1.4 to 11.8 lM across DENV1–4 (Table 1). This is also
in agreement with our previous finding that the overall catalytic
efficacies of DENV1–4 proteases for the substrate Bz-Nle-Lys-Arg-
Arg-AMC differed by two- to sevenfold [22].
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Among several structurally similar compounds, we found two
different types of behaviors. One group, represented by inhibitors
1, 3, 5, and 8, showed selectivity among the different proteases
with inhibition curves that exhibited Hill slopes ranging from 1
to 2. The second group, represented by compounds 2 and 7, had
similar inhibitory effects on different proteases and consistently
displayed Hill slopes much larger than 1 (Table 1), suggesting that
they act as nonspecific inhibitors. Compounds 4, 6, and 9 were
poorly inhibitory or noninhibitory (Table 1).
Trp fluorescence
DENV2 NS2B/NS3pro contains five Trp residues (W5, W50,
W69, W83, and W89) in the NS3pro moiety and one Trp residue
in the NS2B cofactor (W23). Because no three-dimensional struc-
ture of DENV2 NS2B/NS3pro in complex with a ligand is available,
Fig. 2B illustrates the locations of the Trp residues in the structure
of the homologous WNV NS2B/NS3pro (PDB accession code 2FP7
[31]). All Trp residues of DENV2 NS2B/NS3pro are also present in
WNV NS2B/NS3pro [31]. None of the Trps is in the protease cata-
lytic pocket, and the model of the complex with compound 1 sug-
gests the absence of any direct contacts between 1 and any of the
Trp residues. Nonetheless, to test whether Trp fluorescence could
be used to monitor compound binding, we used 1 as a reference
compound. The absorbance spectrum of 1 has two main absorption
bands at 300 and 380 nm (Fig. 3) and overlaps with Trp emission,
usually at 305 to 360 nm. When bound to the protease active site,
compound 1 can potentially influence the fluorescence of the near-
by Trp residues by a FRET. Because 1 has negligible intrinsic fluo-
rescence (data not shown), its binding can be followed by
monitoring the decrease in fluorescence signal intensity of the
Trp residues.
Binding of compound 1
We titrated 4 lM DENV2 NS2B/NS3pro with 1 (0–40 lM) and
monitored fluorescence emission at 340 nm (excitation at
280 nm). The addition of 1 led to fluorescence quenching of the
Trp residues in the protease (Fig. 4A). The effect was not caused
by a change in the environment of the Trp side chains given that
their emission wavelength maximum (kmax) remained unchanged.
A plot of fluorescence intensity versus inhibitor concentration
showed a classical binding isotherm (Fig. 4B). Nevertheless, the ob-
served shallow shape of the binding isotherm indicated that the
protein concentration used was comparable to or below the KD va-
lue of the inhibitor, thereby preventing a good estimate of binding
stoichiometry. Therefore, 1:1 binding stoichiometry was assumed
for all fits to allow comparison among different compounds. The
KD value obtained for 1 was 6 ± 2.6 lM and is comparable to its
IC50 value obtained in the enzyme assay (Table 2).
Fig. 2. Binding of compound 1 in WNV NS3/NS2B protease obtained by automatic
docking with FFLD and CHARMM minimization [39]. (A) Close-up view of WNV
NS3/NS2B in complex with compound 1. The protein surface (PDB code 2FP7) is
colored according to atomic partial charges. Compound 1 is colored by atom type,
and the hydrogens bound to carbon atoms are not shown. The central phthalazine
ring is located in the S1 pocket and forms a p–p interaction with the phenyl group
of Tyr161. Both charged imidazoline groups are involved in salt bridge or hydrogen
bonds with several residues (Asp129, Gly159, and Asn84). One of the NH groups
linking the phenyl and phthalazine moieties hydrogen bonds with Pro131 backbone
carbonyl oxygen. e, elementary charge. (B) Location of trytophan residues in WNV
NS2B/3 protease. The binding pose of compound 1 is shown by green sticks. NS2B is
depicted as blue ribbons, and NS3 is depicted as red ribbons. Tryptophan residues
are represented as yellow sticks and are labeled. The catalytic triad and the
conserved residues of NS3 at the S1, S2, and S3 sites are magenta colored. The
figures were made using PyMOL [40].
Table 1
Results from in vitro testing of compounds on DENV1–4 proteases using substrate Bz-Nle-Lys-Arg-Arg-AMC.
Compound DENV1 DENV2 DENV3 DENV4
IC50 (lM) Hill slope IC50 (lM) Hill slope IC50 (lM) Hill slope IC50 (lM) Hill slope
1 36.4 1.0 6.0 ± 2.6 0.8 17.5 0.9 32.8 0.9
2 2.0 2.4 2.3 ± 0.6 5.1 1.6 3.9 2.0 5.6
3 10.7 1.8 1.1 ± 0.2 0.4 8.5 1.1 13.6 1.6
4 233 1.4 27.4 0.9 100 0.9 64.8 1.3
5 12.3 2.4 5.8 ± 2.3 1.6 8.7 1.4 8.2 2.3
6 170 0.9 55 0.5 86 0.7 43 1.3
7 2.72 2.64 1.6 ± 0.8 3.2 1 3.3 1.3 5.2
8 21.4 1.8 10.2 ± 6.0 0.9 27.9 1.2 19.8 2.4
9 >100 NA >100 NA >100 NA >100 NA
Bz-nKRR-H 11.8 ± 0.9 1.05 8.9 ± 0.5 1.06 7.9 ± 3 1.15 1.4 ± 0.5 0.80
Note. Experiments were performed in 50-ll reaction volumes in a 96-well plate format at 37 C for 30 min. Each IC50 measurement consisted of 40 nM enzyme in 50 mM Tris–
HCl (pH 7.5) and 1 mM Chaps incubated with compound serially diluted from 0 to 100 lM. IC50 values and Hill slopes were obtained by fitting calculated initial velocities to a
nonlinear regression curve using GraphPad Prism software. Each data point was measured in duplicate wells. NA, not applicable.
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Further evidence for binding of 1 to the NS2B/NS3pro catalytic
pocket was provided by using BPTI or aprotinin [33], which is a
known competitive ligand of the protease. BPTI did not induce
any fluorescence change on binding to the protease (data not
shown). When BPTI was added to wells containing DENV2 NS2B/
NS3pro and compound 1, we observed an increase of fluorescence
(Fig. 4B). This indicates that BPTI can displace the binding of 1 and
confirms that the latter binds in the same pocket as BPTI. Compet-
itive binding was also observed with the peptidic inhibitor Bz-
nKRR-H [31] (data not shown).
Which Trp residue is targeted in the quenching experiments?
To decipher which Trp residue was targeted by the quenching
experiments, we systematically mutated the five Trp residues of
DENV2 NS3pro (W5, W50, W69, W83, and W89) to alanine and ti-
trated the mutant proteins with compound 1. Normalized titration
curves revealed that the mutants and wild type (WT) showed sim-
ilar KD values for 1 ranging from 5 to 8 lM (Fig. 4C), with the
exception of the W83A mutant (data not shown). The crystal struc-
tures of DENV and WNV proteases show that W83 is buried, sug-
gesting that W83A mutation destabilizes the protein structure.
W83A was also the least active mutant, with only 1% of the WT
activity (data not shown). Thus, the role of W83 in the fluorescence
studies could not be assessed accurately.
In contrast, the other mutants allowed us to pinpoint Trp resi-
dues affected by inhibitor binding. Most of the fluorescence change
from binding of compound 1 could be attributed to W50 because
mutating this residue to alanine resulted in the least change in
fluorescence signals on titration with compound 1 (Fig. 4C). This
is not surprising given that W50 is in direct proximity of the bind-
ing site [31] (residue H51 is part of the catalytic triad). Thus, the
titration experiment with W50A further ascertained that 1 was
binding to the catalytic pocket. W69 and W89 are also involved
in compound-induced FRET given that mutating these to alanine
likewise resulted in reduction in quenching of the protein intrinsic
fluorescence on titration with compound 1. In contrast, fluores-
cence was unchanged in W5A on titration with compound 1,
implying that this residue plays a negligible role in the signal
change.
Compounds binding to DENV2 protease
For SAR analysis, fluorescence titrations were performed with
63 compounds. Some representative absorbance spectra of the
compounds are shown in Fig. 3. Because the parent compound 1
had the optical properties required to quench tryptophan fluores-
cence, most of the structurally related analogues (all bearing the
central phthalazine rings) from the SAR study had the same prop-
erty. Six of these titrations are represented in Fig. 5A, and the KD
values obtained are listed in Table 2. These compounds spanned
a wide range of IC50 values (1–55 lM). To our surprise, only one
of the four compounds with good IC50 values showed good binding
(3, IC50 = 1.1 lM, KD = 7.7 lM). The binding affinity of 3 was similar
to that of 1 despite a fivefold difference in their IC50 values. Of the
remaining three compounds, one showed intermediate binding (5,
IC50 = 5.8 lM, KD = 18.6 lM), whereas two showed no binding (2
and 7, IC50 = 2.3 and 1.6 lM, respectively). Titration of these com-
pounds with BPTI resulted in displacement of only 3 and 5, con-
firming that only these compounds are competitive binders. No
displacement of BPTI was observed with compounds 2 and 7. These
results are in agreement with the steep Hill slopes observed in the
inhibition curves of DENV1–4 proteases for the latter two com-
pounds. On the other hand, KD values for two compounds that
showed intermediate binding (4 and 8, KD = 22.9 and 16.3 lM,
respectively) correlated well with their IC50 values, and likewise,
two poorly inhibitory compounds (6 and 9, IC50 = 55 and
>100 lM, respectively) were also found to be weak binders or non-
binders. When BPTI was added to the wells after each titration,
competition was observed for compounds 4, 6, and 8 but not 9,
demonstrating their different binding specificities.
Table 2
Results from in vitro inhibition and binding experiments of compounds to DENV2 and WNV proteases.
Compound DENV2 IC50
(lM)
DENV2 KD
(lM)a
DENV2 competition
ITCb
DENV2 KD (lM)
by ITCc
DENV2 KD (lM)
by SPR
WNV IC50
(lM)
Hill slope WNV KD
(lM)
1 6 ± 2.6 7.2 ± 3.2 (Y) Y 7.3 3.7 24.5 3.5 21
2 2.3 ± 0.6 NB (N) N NB NB 3.6 ± 1.8 2.6 NB
3 1.1 ± 0.2 7.7 ± 2.0 (Y) Y 13 0.3 22 1.4 90
4 27.4 22.9 (Y) nd nd nd 5.2 1.0 4.6
5 5.8 ± 2.3 18.6 (Y) Y 17 >100 10.6 1.9 100
6 55 54 (Y) nd nd nd 6.2 1.1 7
7 1.6 ± 0.8 NB (N) N NB nd 2.2 3.0 NB
8 10.2 ± 6.0 16.3 ± 0.3 (Y) Y 40 4.3 16 2.0 nd
9 >100 100 (N) N NB NB nd nd nd
Note. Determination of IC50 values obtained were as described for Table 1. Compounds were tested for binding to DENV2 and WNV proteases using fluorescence quench assay,
ITC, and SPR as described in Materials and methods.
a Y (yes) and N (no) indicate whether or not competition was observed between compound and BPTI.
b Competition ITC reflects a qualitative judgment of the competition data based on both change in KD and change in binding enthalpy. Y and N, see note a; NB, no binding;
nd, experiment not done.
c For compound 1, the KD value was calculated based on a single concentration of compound 1, whereas the KD values for compounds 3 and 8 were determined from several
compound concentrations using Eq. (2).
Fig. 3. Absorbance spectra of compounds 1 to 7 (100 lM) measured on a 96-well
plate with a microplate reader. Compound numbers are indicated.
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Compounds binding to WNV protease
WNV and DENV proteases are homologous proteins but show
different sensitivities toward different compounds. For example,
compound 6 displayed a relatively low IC50 value for WNV prote-
ase (6.2 lM) but not for DENV2 (55 lM) (Table 2). This raised
the question as to whether the tryptophan fluorescence assay
would detect these differences. The same fluorescence quenching
experiments can be applied for WNV and DENV proteases because
tryptophans are present in both proteins at the same positions. We
titrated WNV with the compounds as before and obtained a KD va-
lue for compound 1 that was similar to its IC50 value (Fig. 5B and
Table 2). Interestingly, two compounds that were weak inhibitors
and binders to DENV2 protease displayed good IC50 values and
good binding affinities to WNV protease (compounds 4 and 6,
KD = 4.6 and 7.0 lM, respectively). Conversely, some of the com-
pounds that were more potent against DENV than WNV bound
only weakly to the WNV protease and showed poor KD values for
the latter (compounds 3 and 5, KD = 90 and 100 lM, respectively).
Finally, compounds 2 and 7, which showed comparable IC50 values
in DENV2 and WNV, also did not bind to WNV.
Isothermal titration calorimetry
ITC was used to corroborate the binding affinities obtained by
tryptophan fluorescence. Due to low compound binding affinities
and low solubilities, no satisfactory data were obtained in ITC
experiments where the compounds were directly titrated to the
DENV2 protease. To circumvent this experimental barrier, we
performed competition ITC using BPTI. Titration of 6 lM protease
with 80 lM BPTI resulted in exothermic binding and gave
KD = 19 nM, n = 1.19, and DH = 5.5 kcal/mol (Fig. 6). Competition
experiments were performed by titrating the protein–BPTI com-
plex with different compounds. Fig. 6 shows representative
examples of titrations performed with compounds 3, 8, and 9.
Compound 9 was used as a control because it did not inhibit
the protease activity and did not show any binding to the prote-
ase by fluorescence (Table 2). The addition of 100 lM compound
9 did not induce any significant change in the apparent KD or on
the binding enthalpy of BPTI (30 nM or 5.4 kcal/mol, respec-
Fig. 4. Titration of DENV2 protease with compound 1. (A) Fluorescence spectra of
DENV2 protease at various protein concentrations. The kinks in the spectra at 400
nm are an artifact of the microplate reader. AU, arbitrary units. (B) Titration of WT
DENV2 protease with compound 1 monitored by fluorescence at 340 nm. The solid
line is the fit of the data to Eq. (1). The symbol (h) shows the level of fluorescence
reached after the addition of 11 lM BPTI to the well containing WT protein and 40
lM compound 1. (C) Titration of WT and W mutants with compound 1. Shown is
normalized fluorescence at 340 nm (measured fluorescence [F] divided by the
fluorescence measured in the absence of compound [F0]). The solid lines are the fit
of the data to Eq. (1). Symbols: WT (d); W5A (s); W50A (j); W69A (D); W89A (e).
The resulting KD values were 4.7, 5.15, 6.2, 6.6, and 7.8 lM, respectively.
Fig. 5. Fluorescence titrations performed with several compounds. Titration data
were normalized by dividing the measured fluorescence (F) by the fluorescence
measured in the absence of compound (F0). (A) Titration of DENV2 protease. (B)
Titration of WNV protease. Solid lines show the fit of the data to Eq. (1). Titrations
with different compounds are represented as follows: 1 (D); 2 (d); 3 (e); 4 (j); 5
(); 6 (h); 7 (s).
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tively). In contrast, 100 lM compound 3 and 150 lM compound
8 resulted in the following respective changes in BPTI binding:
KD = 125 nM and DH = 3 kcal/mol; KD = 77 nM and DH =
2.6 kcal/mol. Other compounds were also tested for competi-
tion by ITC (Table 2). In summary, based on changes observed
in the apparent KD and/or on the binding enthalpy for BPTI, com-
pounds that clearly competed with BPTI binding were 1, 3, 5, and
8, whereas noncompeting compounds were 2 and 9. Results from
ITC experiments concurred with the previous fluorescence
quenching data in that compounds 1, 3, 5, and 8 were identified
as specific protease binders. Conversely, compounds that showed
no binding in fluorescence were also negative in ITC (2 and 7).
Surface plasmon resonance
Binding affinities between compounds 1, 2, 3, 5, 8, and 9 and
DENV2 protease were evaluated using a surface plasmon reso-
nance (SPR) biosensor. DENV2 protease was immobilized on the
matrix via an engineered C-terminal cysteine, and increasing con-
centrations of compounds were passed across (78 nM to 12.5 lM).
The results are summarized in Table 2. In general, the compounds
showed fast on and off rates in this concentration range. Com-
pounds 1 and 8 gave satisfactory sensorgrams, allowing a straight-
forward analysis. Binding affinity for compound 1 was evaluated
by fitting the data to the 1:1 Langmuir (see Fig. S2 in Supplemen-
tary material) and steady-state models (data not shown), returning
similar KD values of 3.75 and 2 lM, respectively. However, at con-
centrations above 12.5 lM, we observed deviations from the 1:1
fit, presumably due to nonspecific binding to the immobilized pro-
tein or carboxymethyl matrix. A competition assay showed that
BPTI completely displaced 1 from its binding site on the protease
(see Fig. S3). This corroborated results from other biophysical
methods tested that compound 1 shares part of the binding site
of BPTI.
Following a steady-state model, compound 8 yielded a KD value
of 4.3 lM. Compounds 2, 3, 5, and 9 displayed evidence of nonspe-
cific interactions. Following the addition of 150 mM NaCl to the
phosphate buffer, specific binding was observed for compound 3
(KD = 0.3 lM) but not for compound 5 (KD > 100 lM). Nonspecific
binding persisted for compounds 2 and 9.
Discussion
Our study highlights the importance in drug discovery to con-
firm IC50 measurements with binding assays. The Trp fluorescence
quenching assay presented here provided information on the bind-
ing mode of the compounds, including their binding site and the
tightness of association. Using this assay, we systematically mea-
sured the binding affinities of 63 compounds generated from the
SAR study and compared the KD values obtained with their IC50 val-
ues (data not shown). We observed that, in a number of instances,
small modifications of compound structures led to dramatic
changes in specificity of inhibition. These changes were not always
detectable by IC50 measurements. Nine key compounds were fur-
ther characterized and are presented in this article.
We believe that changes in intrinsic fluorescence of the prote-
ase on compound binding was caused by a FRET mechanism where
the compounds acted mainly as Trp fluorescence acceptors and
were not due to an effect on Tyr residues. First, compound binding
experiments that were performed with an excitation wavelength
of 295 nm where Tyr was not excited gave similar binding iso-
therms and KD values as experiments performed at 280 nm. Sec-
ond, studies with Trp-to-Ala mutants showed that fluorescence
change induced on compound binding was due mostly to W50 in
the NS3 moiety. W50 is the Trp residue nearest to the active site,
and in the cocomplexed WNV protease Bz-nKRR-H crystal struc-
ture [31] the C–a distance between W50 and the center of the pep-
tide is approximately 10 to 15 Å. Förster distances FR (where FR
corresponds to the distance where 50% FRET efficacy is observed)
of 6 to 12 and 21 Å have been reported for Trp–Trp homotransfer
and Trp–dansyl pairs [34], respectively. Because the distance be-
tween W50 and the compound falls within this range, the signifi-
cant FRET observed is fully expected.
A potential pitfall associated with fluorescence spectroscopy is
the inner filter effect (IFE) that arises when the absorbance of the
sample becomes too high at the excitation and emission wave-
lengths. The IFE causes a nonlinearity of the fluorescence signal
that can be estimated by
IFobs ¼ IF  10ð
AexþAem
2 Þ; ð3Þ
where IFobs is the measured fluorescence, IF is the fluorescence after
IFE correction, and Aex and Aem are the absorbances at the excitation
and emission wavelengths, respectively [35]. The compounds tested
in this study absorbed at both 280 and 340 nm so that, in principle,
IFE could have contributed to the signal change observed. A control
experiment where 15-lM solutions of N-acetyl-tryptophanamide
were titrated with four of the compounds showed, however, that
IFE is only minimally responsible for the fluorescence decrease
(see Fig. S4 in Supplementary material). Therefore, the hyperbolic
shapes observed in the titration experiments of the protease were
indeed due to specific binding.
Our goal in developing a binding assay based on Trp fluores-
cence was to screen out nonspecific inhibitors and to ascertain
whether compounds were binding competitively to the enzyme.
A total of 63 compounds were tested in our study for their inhibi-
tory capabilities (IC50) and their binding affinities (KD). This ap-
proach identified promiscuous inhibitors, and using BPTI we
demonstrated that only a subset of compounds with low KD were
truly competitive binders (data not shown). Inclusion of Triton X-
100 in the assay can often discriminate specific from nonspecific
inhibitors that act via the formation of colloidal aggregates [5,6].
However, not all enzyme assays can tolerate the addition of Triton
X-100. Moreover, because the promiscuous nature of some inhibi-
tors also depends on the protein target, this method cannot elimi-
nate all false positives [3]. Our attempts to eliminate nonspecific
binders by the addition of Triton X-100 in the enzyme assay was
not very successful given that even the reference inhibitor Bz-
nKRR-H showed at least fivefold change in IC50 values in the pres-
ence of the detergent (data not shown).
Fig. 6. ITC competition titration. Titrations of 6 lM DENV2 protease with 28
consecutive 10-ll injections of 80 lM BPTI at 25 C were performed in the presence
of various concentrations of compounds. Typical titrations are shown in the absence
of compound (s) and in the presence of 150 lM compound 8 (j), 100 lM
compound 3 (D), and 100 lM compound 9 (.).
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Compound 1, which was the parental compound from which
SAR was developed, showed comparable IC50 (6 ± 2.6 lM) and KD
values from Trp fluorescence (7.5 ± 3.2 lM) and ITC (7.3 lM) as
well as SPR (3.75 lM) for DENV2 protease. We further observed
competition of 1 with BPTI by ITC, SPR, and fluorescence quench-
ing. NMR experiments confirmed that it interacted with the DENV2
protease active site (see Fig. S1 in Supplementary material). Com-
pound 1 showed some differences in affinities for different dengue
serotypes (IC50 values varied between 6 lM for DENV2 and 33 lM
for DENV4), and the Hill slopes obtained were close to 1, indicating
a specific mode of inhibition [36,37]. The same is true for com-
pounds 3 and 8.
On the other hand, compound 2 displayed one of the best IC50
values in our SAR analysis (2.3 ± 0.6 lM for DENV2 protease). De-
spite its potency, no binding was detected by Trp fluorescence, and
the addition of BPTI after the titration did not induce any decrease
in fluorescence intensity. This was confirmed by ITC where no
competition with BPTI was observed and again by the absence of
binding in SPR. Hence, it is likely that compound 2 is a nonspecific
inhibitor. This reasoning also applies to compound 7. Careful
inspection of the enzyme inhibition data for WNV and DENV1–4
proteases revealed two variables as particularly useful criteria of
specific binding. First, the inhibition curves obtained with 2 and
7 displayed steep transitions. This translated into steep Hill slopes,
strongly suggesting that they act by a nonspecific mechanism
[36,37]. Relying solely on Hill slopes, however, may be misleading.
For example, compounds 3, 5, and 8 gave Hill slopes of approxi-
mately 2 (Table 1), yet data from fluorescence quenching experi-
ments and ITC clearly showed that they were specific inhibitors.
These examples reinforce our conclusion that it is important to
use a repertoire of biochemical and biophysical techniques to accu-
rately determine compound binding specificity during drug
screening.
Second, IC50 values obtained with compounds 2 and 7 were very
similar for WNV and DENV1–4, indicating that they inhibited all
proteases equally well. This is unexpected considering that the
S1 site of the WNV protease catalytic pocket differs from those of
DENV1–4 proteases and NS2B residues forming S2 and S3 sites
are also not well conserved between WNV and the different DENV
serotypes. Moreover, the transition state analogue Bz-nKRR-H
showed different inhibition properties with proteases from the dif-
ferent dengue serotypes (Table 1) and WNV [13]. We conclude that
in the current SAR, similar IC50 values observed for the different
serotypes, coupled with high Hill slopes, were indicative of non-
specific inhibition.
As described in this article, we also explored other biophysical
techniques besides Trp fluorescence, such as NMR, ITC, and SPR,
to evaluate the binding characteristics of compounds from our
SAR study. Because our most active compounds showed IC50 values
between 1 and 10 lM, they were tested at relatively high concen-
trations (>100 lM) in both NMR and ITC. Thus, the major issue we
encountered was low compound solubility that prevented mean-
ingful analyses using these methods. Consequently, NMR and ITC
offered a mostly qualitative observation (binding or no binding),
whereas quantitative binding parameters (rather than binary an-
swers) are paramount for understanding SAR. Because compounds
identified during hit-to-lead and early lead optimization phases of-
ten have relatively low potency (>1 lM) and are usually hydropho-
bic in nature [38], compound insolubility in NMR and ITC would
result in these compounds being eliminated from follow-up stud-
ies even if they are specific inhibitors. With SPR, we observed a cor-
relation with KD measured by fluorescence for most of the
compounds except compound 5. The compound could have aggre-
gated from nonspecific interactions with the immobilized protease
or chip matrix. In contrast, we rarely faced solubility or aggregation
problems in the fluorescence quenching assay with the concentra-
tions of compounds tested (up to 40 lM) and were able to quantify
the binding affinities of most specific compounds.
The Trp fluorescence assay presented here was a very useful
tool for our drug discovery effort because it discriminated between
specific and nonspecific compounds from our SAR study. This
method has many advantages. First, small amounts of purified re-
combinant proteins can be readily used without the need to further
label or tag them. Second, fluorescence spectroscopy tolerates a
wide range of buffer conditions, salts, detergents, and reducing
agents. Third, the binding assay can be done in 96- or 384-well for-
mats, making this method amenable to automation further
increasing the throughput. Fourth, the sensitivity of this method
allows measurements of KD values in the range from 0.1 to
20 lM. Below 0.1 lM the shape of the binding curve would not
permit a precise determination of the KD value, whereas above
20 lM the IFE would obscure fluorescence decrease induced by li-
gand–protein binding. Assays sensitive to this range of KD values
are of great value in the critical drug discovery phases of hit-to-
lead conversion and early lead optimization.
Because Trp is present in most proteins, the Trp fluorescence
quenching assay presented here is applicable to other studies of
protein–compound interaction. If Trp residues are absent or far
from the binding site, they may be introduced by site-directed
mutagenesis. The simplest manner to detect compound binding
is via direct compound quenching of Trp fluorescence, as shown
in this article, or by observing changes in the Trp emission maxima.
Most compounds in drug discovery follow the Lipinski rules [38]
and are largely hydrophobic, and often aromatic, molecules. Absor-
bance spectra of such compounds often span the spectral range
from 270 to 400 nm, making them suitable quenchers of trypto-
phan fluorescence. If a class of compounds lacked these spectro-
scopic properties, a known inhibitor that induces a fluorescence
change on binding could be used as a competitor. The ease of
implementing this technique makes it well-suited for drug discov-
ery needs.
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